- Pfizer deals extend patent life for a top-selling rare disease drugSettlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.BioPharma Dive · 3mo ago↗ source
- Boehringer dual-acting obesity shot hits mark in Phase 3 trialSurvodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.BioPharma Dive · 3mo ago↗ source
- FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsTavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.